Please assess the completion status of the following clinical trial:

Trial Title: Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver Reserve

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Patients with measurable, metastatic or locally advanced hepatocellular carcinoma~2. The diagnosis of HCC should be established either by cyto/histology~3. Patients must be \> 20 years of age.~4. ECOG score \< 2.~5. Signed informed consent.~6. Female patients at child-bearing age must have negative pregnancy test.~Exclusion Criteria:~1. Patients with other systemic diseases which require concurrent usage of glucocorticosteroid or immunosuppressant agent(s) are not eligible.~2. Patients with advanced second primary malignancy are not eligible.~3. Patients with active infection are not eligible.~4. Patients with pregnancy or breast-feeding are not eligible.~5. Patients with brain metastases are not eligible.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).